ASKA Pharmaceutical Holdings Co.,Ltd.

TSE:4886 Stok Raporu

Piyasa değeri: JP¥60.3b

ASKA Pharmaceutical HoldingsLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

ASKA Pharmaceutical HoldingsLtd has been growing earnings at an average annual rate of 37.7%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 5% per year. ASKA Pharmaceutical HoldingsLtd's return on equity is 11.7%, and it has net margins of 11.7%.

Anahtar bilgiler

37.7%

Kazanç büyüme oranı

37.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi3.4%
Gelir büyüme oranı5.0%
Özkaynak getirisi11.7%
Net Marj11.7%
Sonraki Kazanç Güncellemesi05 Nov 2024

Yakın geçmiş performans güncellemeleri

ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Solid Profits Have Weak Fundamentals

May 21
ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Solid Profits Have Weak Fundamentals

Recent updates

ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Solid Profits Have Weak Fundamentals

May 21
ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Solid Profits Have Weak Fundamentals

Gelir ve Gider Dağılımı

ASKA Pharmaceutical HoldingsLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

TSE:4886 Gelir, gider ve kazançlar (JPY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2463,1727,39020,0904,728
31 Mar 2462,8437,54519,4364,728
31 Dec 2362,0266,51320,0294,227
30 Sep 2361,9376,02119,9574,227
30 Jun 2361,2154,34319,4214,227
31 Mar 2360,4614,23819,2494,227
31 Dec 2259,6874,39119,2653,598
30 Sep 2258,3029,43218,6123,598
30 Jun 2257,6554,51518,0443,598
31 Mar 2256,6074,29017,9583,598
31 Dec 2156,0104,34421,2400
30 Sep 2156,255-1,63521,6470
30 Jun 2155,6883,07222,0990
31 Mar 2155,1812,71321,7730
31 Dec 2054,6852,03617,1034,913
30 Sep 2053,3631,62417,1474,913
30 Jun 2052,26582516,9804,913
31 Mar 2052,54264917,5964,913
31 Dec 1950,89759217,2534,493
30 Sep 1949,8111,57815,4714,493
30 Jun 1947,9361,24514,3194,493
31 Mar 1946,7061,74412,6144,493
31 Dec 1847,2471,57812,5074,055
30 Sep 1847,3671,48812,5424,055
30 Jun 1848,8922,40712,1054,055
31 Mar 1848,9442,38812,0054,055
31 Dec 1749,7652,06011,6254,970
30 Sep 1749,2653,31212,1424,970
30 Jun 1749,3533,46112,1164,970
31 Mar 1748,5272,94412,1494,970
31 Dec 1647,1583,53112,0844,174
30 Sep 1646,4241,58111,8894,174
30 Jun 1644,4791,04011,7264,174
31 Mar 1643,21570111,8044,174
31 Dec 1542,72179212,5064,025
30 Sep 1540,81975211,8704,025
30 Jun 1543,1971,08511,8504,025
31 Mar 1542,9071,19311,7424,025
31 Dec 1442,33569511,4924,144
30 Sep 1442,67080911,9044,144
30 Jun 1439,39328212,2094,144
31 Mar 1439,50149512,2094,144
31 Dec 1340,6321,00012,4874,269

Kaliteli Kazançlar: 4886 has a large one-off gain of ¥3.3B impacting its last 12 months of financial results to 30th June, 2024.

Büyüyen Kar Marjı: 4886's current net profit margins (11.7%) are higher than last year (7.1%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4886's earnings have grown significantly by 37.7% per year over the past 5 years.

Büyüme Hızlandırma: 4886's earnings growth over the past year (70.2%) exceeds its 5-year average (37.7% per year).

Kazançlar vs. Sektör: 4886 earnings growth over the past year (70.2%) exceeded the Pharmaceuticals industry 38.7%.


Özkaynak Getirisi

Yüksek ROE: 4886's Return on Equity (11.7%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin